What did @thepcosmentor actually say?
This video is not a medical claim. It is a call for empathy. @thepcosmentor argues that criticizing someone for choosing or declining GLP-1 medications for PCOS is unfair because "you don't know their struggles" or "what their doctors have seen or found." The creator explicitly says the video is "not for or against" GLP-1s and positions it as a defense of patient autonomy and compassion. That framing matters, because it changes what we are actually fact-checking here. There are no specific efficacy claims, no dosing advice, and no promises about outcomes. What the creator is really saying is that PCOS treatment decisions are personal and complex, and that online judgment is unhelpful. On that narrow point, they are largely correct, even if the video sidesteps the clinical nuance that patients actually need.
Does the science back this up?
The idea that PCOS treatment is deeply individual is well-supported. Research does confirm that GLP-1 receptor agonists show real promise for certain PCOS presentations, but the evidence base is still maturing. A 2023 systematic review by Khajehei et al. in Frontiers in Endocrinology found that semaglutide and liraglutide improved metabolic markers and androgen levels in women with PCOS, particularly those with obesity or insulin resistance. However, the authors were careful to note that most trials were small, short-term, and not adequately powered. A 2022 RCT by Cena et al. in Journal of Clinical Medicine showed liraglutide reduced body weight and improved menstrual regularity in PCOS patients, but remission was not universal. In other words, GLP-1s help some women with PCOS meaningfully and do little for others. The creator's point that individual medical history shapes the decision is not just emotionally reasonable; it reflects how prescribers actually approach this condition.
What did they get wrong (or right)?
What they got right: PCOS is genuinely difficult to treat. It is a heterogeneous condition with at least four recognized phenotypes (Rotterdam criteria), meaning two women with the same diagnosis can have almost nothing in common metabolically. Blanket judgments about any treatment choice ignore that reality entirely. The creator gets credit for that implicit acknowledgment. What they left out, and this is where the video falls short for anyone actually making a health decision, is any signal about who GLP-1s are most likely to help. Women with lean PCOS, for example, may have a very different risk-benefit profile than those with insulin-resistant PCOS. Omitting that is not misinformation, but it is a gap. The "you don't know their story" framing, while emotionally valid, can also accidentally discourage people from asking harder questions of their own clinicians. Compassion and critical thinking are not mutually exclusive.
What should you actually know?
If you have PCOS and are considering a GLP-1, a few things are worth knowing beyond the compassion framing. First, GLP-1 receptor agonists are not FDA-approved specifically for PCOS. Their use in this context is off-label, which is legal and common but means the evidence standards are lower than for approved indications. Second, metabolic subtype matters. A 2021 analysis by Lim et al. in Human Reproduction Update found that insulin resistance affects roughly 65-70% of women with PCOS regardless of BMI, which is the population most likely to see benefit from insulin-sensitizing or GLP-1-class therapies. Third, GLP-1s carry real side effects including nausea, pancreatitis risk, and potential thyroid concerns that deserve a conversation with a prescriber, not a TikTok comment section. The creator is right that judgment from strangers is useless. But the answer to bad online discourse is not just more empathy. It is better access to actual clinical guidance.